ArticleStem cell research & therapy2025
Endothelial cell-targeting aptamer-empowered exosomes accelerate wound healing by promoting specialized angiogenesis in type 1 diabetic mice.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gli1⁺ cell aggregates promote type H vessel formation and orchestrate bone defect regeneration.Stem cell research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundThe reduced angiogenesis in diabetes mellitus (DM) represents a critical barrier to effective skin wound healing. Therapeutic strategies involving mesenchymal stem cells (MSCs) and MSC-derived exosomes (EXOs) have demonstrated potential in promoting wound healing in diabetic contexts. However, each approach presents specific limitations.
methodsApt-PEG-DSPE was synthesized via amide condensation between DSPE-PEG-COOH and NH₂-Apt, followed by incubation with EXOs to yield Apt-EXOs, then mixed with HA to form Apt-EXOs-HA. C57BL/6 mice were injected intraperitoneally with 50 mg/kg STZ daily for 5 days to induce a type 1 diabetes (T1D) model. Under anesthesia, dorsal fur was shaved and full-thickness skin defects (1.0 cm diameter) were created. The therapeutic effect of Apt-EXOs-HA on skin wound healing in T1D was evaluated by assessing wound closure, vascularization and collagen deposition. The Student's t-test (two-tailed) was used to assess statistical significance.
resultsIn this study, we identified that vascular structures, specifically CD31⁺EMCN⁺ vessels, are impaired in T1D, and this impairment contributes to delayed wound healing and aberrant collagen deposition. Following proteomic analysis and related vascular endothelial cell experiments (including cell migration and tube formation) demonstrating the superior angiogenic potential of EXOs compared to MSCs, we engineered endothelial-targeting EXOs by conjugating them with aptamers (Apt). The application of these Apt-conjugated EXOs in combination with a hyaluronic acid scaffold significantly enhanced angiogenesis under both physiological and DM conditions, thereby accelerating wound healing.
conclusionsCollectively, our findings emphasize the essential role of specialized angiogenesis in wound repair and propose a novel, advanced EXOs modification-based therapeutic approach to enhance wound healing in both normal and diabetes-related pathophysiological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.